#Netherlands #Utrecht #ViCentra #Kaleido #Tom Arnold

ViCentra's New Leadership: Tom Arnold Takes the Helm

In a significant move aimed at expanding its market presence, ViCentra B.V. has appointed Tom Arnold as its new Chief Executive Officer. ViCentra, renowned for its innovative Kaleido insulin patch pump, hopes to leverage Arnold's extensive experience in the medical technology sector to scale operations and enhance accessibility for diabetes care worldwide.

A Leader with Proven Expertise

Tom Arnold is no stranger to the challenges and opportunities within the diabetes care industry. With nearly 25 years in leadership roles at reputable companies like Medtronic, Boston Scientific, and PROCEPT BioRobotics, Arnold has a distinguished track record of driving commercialization initiatives and launching groundbreaking medical products. His tenure at Medtronic included pivotal contributions to the introduction of the world’s first hybrid closed-loop insulin pump, where he successfully navigated innovative commercialization strategies that increased patient access to critical diabetes management solutions.

ViCentra's Chairman of the Board, Jan Keltjens, expressed strong confidence in Arnold’s appointment, citing his deep knowledge of the healthcare landscape and personal connection to the diabetes community. "Tom’s unique qualifications will steer ViCentra towards its next growth phase," Keltjens stated. This sentiment is especially poignant considering Tom's personal connection to the cause, as his youngest daughter has lived with type 1 diabetes since she was an infant.

Commitment to Innovation

An integral part of Arnold's mission at ViCentra will be to continue refining Kaleido, a highly advanced insulin delivery system that prides itself on being one of the smallest and lightest available. Kaleido combines cutting-edge technology, creating a user-friendly experience for those managing diabetes. The product's current user base of approximately 2,500 across Europe reflects its warm reception, and Arnold aims to broaden these numbers significantly.

Arnold's deep understanding of diabetes management, compounded by his experiences as a father dealing with the disease, will play a crucial role in his leadership. He remarked, "As both a MedTech leader and a father, I resonate with the daily hurdles faced by individuals managing diabetes. The mission at ViCentra—making insulin therapy more adaptable and impactful—aligns perfectly with my personal and professional goals."

The Road Ahead

With a vision to expand into untapped markets, including a strong emphasis on the U.S. sector, Arnold has laid out plans to enhance ViCentra's global footprint. Under his leadership, the company intends to drive innovative partnerships and accelerate production capabilities to meet growing demands.

Kaleido is not just an insulin pump; it's a lifestyle solution designed to empower users. Offering versatility, it can be utilized either as a patch or via a tubed option, catering to diverse user preferences. The device is also available in an array of vibrant colors, allowing users to express their individuality while managing their health

About ViCentra

Founded in 2013 and based in Utrecht, The Netherlands, ViCentra is committed to revolutionizing diabetes management. Backed by prominent investment firms, the company’s spotlight product, Kaleido, is already CE-marked and marketed in several European nations. ViCentra seeks to expand this reach, ensuring that people living with diabetes can lead fulfilling lives tailored to their unique needs. With Tom Arnold at the forefront, the company is poised for exciting developments in the near future.

For more information about ViCentra and its innovative solutions for diabetes care, visit www.hellokaleido.com.